Dr. Carol Aghajanian on the Angiogenesis Inhibitor Pazopanib in Ovarian Cancer

Dr. Aghajanian Discusses Clinical Trial Endpoints in Ovarian CancerПодробнее

Dr. Aghajanian Discusses PARP Inhibitors for the Treatment of Ovarian CancerПодробнее

Dr. Andreas du Bois Reviews Maintenance Pazopanib in Ovarian CancerПодробнее

ASCO 2013: Delayed relapse of advanced ovarian cancer when treating with pazopanibПодробнее

New Ovarian Cancer Research and Treatments | Memorial Sloan KetteringПодробнее

ESMO 2014: Inhibition of PARP, angiogenesis and immune checkpoints for ovarian cancer managementПодробнее

Strategies for Managing Long Term Recurrent Ovarian CancerПодробнее

Dr. Carol Aghajanian on Clincal Trial Endpoints in Ovarian CancerПодробнее

Pazopanib delays progression of advanced ovarian cancerПодробнее

Dr. Eng: Continuation of Anti-Angiogenesis TherapyПодробнее

BRCA and RAB: prognostic biomarkers in recurrent ovarian cancerПодробнее

Treatment After Third-Line Therapy in Ovarian CancerПодробнее

PARP Inhibition in Ovarian CancerПодробнее

Targeted Therapy in Newly Diagnosed Advanced Ovarian CancerПодробнее

Managing Angiogenesis Inhibitor Associated Skin ToxicityПодробнее

Role of Anti-angiogenesis in Ovarian Cancer Dr. Thomas HerzogПодробнее

Role of the Anti-angiogenesis in Ovarian Cancer Dr. Thomas Herzog Day 1 2021Подробнее

Joanne Mortimer, MD: Pazopanib Maintenance TherapyПодробнее

Dr. Konner on PARP Inhibitors in Ovarian CancerПодробнее